Skip to main content
Log in

Should the Philosophy of Postmarketing Surveillance in the US be Redefined?

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. La Puma J. Physician rewards for postmarketing surveillance (seeding studies) in the US. PharmacoEconomics 1995; 7 (3): 187–90

    Article  PubMed  Google Scholar 

  2. Members ofthe ASCPT Pharmacoepidemiology Section. Notes of the American Society for Clinical Pharmacology and Therapeutics: position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clin Pharmacol Ther 1990; 48: 598

    Article  Google Scholar 

  3. Jefferys DB, Jones KH. EMEA and the new pharmaceutical procedures for Europe. Eur J Clin Pharmacol 1995; 47: 471–6

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Soto, J., Sacristan, J.A. Should the Philosophy of Postmarketing Surveillance in the US be Redefined?. Pharmacoeconomics 8, 175–176 (1995). https://doi.org/10.2165/00019053-199508020-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199508020-00009

Keywords

Navigation